DexCom, Inc. (DXCM)

From the record

DexCom, Inc.'s filings since 2017 show 1 warning event: an auditor change (8-K item 4.01, the latest 2025-03-25) (its current reports).

From the record

DexCom, Inc.'s 10 filed years say what it did: revenue went from $573 million in fiscal 2016 to $4.7 billion in fiscal 2025, up 26.2% a year; it rose in 9 of 9 years; it never fell from a peak; net income was positive in 7 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, DexCom, Inc.'s diluted share count shrank about 1.7% a year, and dividends and buybacks returned about 61% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 31 sales (31 under scheduled 10b5-1 plans) and 0 purchases of their own stock on the open market in the year to 2026-11-10 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, DexCom, Inc. earned about 30 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 44 cents per dollar of everything the company owns. Leverage: it owed about 57 cents per dollar of assets, and net share issuance: its share count shrank 1.7% over the year (the filed statements).

From the record

DexCom, Inc.'s standing among 109 graded names in its industry family: revenue of $4.7 billion in fiscal 2025 ranks in the top 8% by size; a net margin of 17.9% ranks in the top 9%; revenue growth of 17% a year over the last 3 filed years ranks in the top 44% (its annual reports).

From the record

DexCom, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Leach, Jacob Steven (President, CEO, and Director, as filed), filing under that title since 2026-02-02, 9 months (bottom 17% of its family); the 17 officers and directors filing in the last fifteen months have been on the record a median of 6.1 years (top 40%); 13 officer or director changes were reported on Form 8-K since 2023-11-13, against the 17 people in charge now (bottom 29%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

DexCom, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $918 million against no long-term debt tagged leaves 14.5% of its assets as net cash, top 44% of its family; cash from operations less capital spending is 23.1% of revenue (top 6%); a gross margin of 60.1% (bottom 48%); research spending of 12.9% of revenue (top 46%) (its annual report).

From the record

DexCom, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 17% a year over the last three filed years against 26.2% over all 10, slowing (bottom 28% of its family); the newest year grew 15.6% (top 44%); research spending grew 7.4% a year (top 46%); capital spending grew -0.1% a year (top 50%) (its annual reports). DexCom, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

From the record

DexCom, Inc.'s newest year against its own record: revenue of $4.7 billion in fiscal 2025 came in 1.8% below the $4.7 billion its prior three years' pace pointed to (top 46% of its family); net income of $836 million against a prior three-year average of $486 million (top 24%); a net margin of 17.9% against 13.7% before (bottom 39%) (its annual reports).